(Reuters) -Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the ...

By Twesha Dikshit and Ragini Mathur (Reuters) -European shares closed flat on Wednesday, surrendering early session gains, as ...

If a deal is confirmed and consummated, Novartis would claim ownership of a biotech that has raised something of a stir in ...

Avidity Biosciences (NASDAQ:RNA) stock surged 18% Wednesday after the Financial Times reported that Swiss pharmaceutical ...

--Novartis made a takeover approach for Avidity Biosciences, a biotechnology company that specializes in rare diseases with a market value of $5.8 billion, the Financial Times reports, citing unnamed ...

Meanwhile, mRNA vaccine maker Moderna is cutting around 500 jobs (10% of its workforce) as part of a commitment to save $1.5 ...

Avidity Biosciences ( NASDAQ: RNA) quickly soared 20% after a report that Novartis ( NYSE: NVS) made a takeover approach for the rare-disease maker.

The US Food and Drug Administration (FDA) has approved a label expansion to Teva’s Ajovy in certain children and adolescents, ...

The US Food and Drug Administration approved the revised label for inclisiran, a small interfering RNA that reduces the ...

After weeks of working with U.S. officials to try to avoid hefty tariffs on Swiss goods, negotiators from Switzerland got ...

Switzerland is now paying one of Donald Trump’s highest tariffs after the government failed in its last-ditch effort to get ...

Glencore maintains its UK listing; Britain seeks clarity on China's embassy plans; Novartis considers acquiring biotech firm ...